Concepedia

Publication | Open Access

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma

DOIFull Paper Access

13

Citations

23

References

2022

Year

Maojin You, Yufan Huang, Zhongjie Cai, Qingfeng Wu, Wei Zhu, Ying He, Ruijia Chen
Frontiers in Oncology

Abstract

From the Chinese healthcare system perspective, SIDCHM is considered a cost-effective treatment option compared with PLCHM as first-line therapy for advanced or metastatic ESCC.

References

YearCitations

Page 1